The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $538,925 in first-year total cost, median $164,306.
Most frequent study sections
- Special Emphasis Panel[ZHD1 DSR-K (50)]3
Most frequent institutions
- CICERODX, INC.1
- DOT LABORATORIES, INC.1
- RIBOMED BIOTECHNOLOGIES, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Multi-center prospective study assessing a panel of microRNAs as a non-invasive test for endometriosis1R43HD097720-01 | TAYLOR, HUGH SMITHWINGROVE, JAMES ALAN | DOT LABORATORIES, INC., CA | $224,619 | ZHD1 |
| 2019 | Non-Invasive Assay for Diagnosis and Treatment of Endometriosis1R43HD097719-01 | MCCARTHY, DAVID R | RIBOMED BIOTECHNOLOGIES, INC., AZ | $164,306 | ZHD1 |
| 2019 | SIRT1 and BCL6: Dual Biomarkers of Endometriosis and Endometrial Receptivity1R44HD097750-01 | ANGRESS, DAN | CICERODX, INC., CA | $150,000 | ZHD1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.